The Europe In-Vitro Diagnostics Market Report is Segmented by Test Type (Clinical Chemistry, and More), Product & Service (Instrument, and More), Usability (Disposable IVD Devices, and More), Specimen Type (Blood, and More), Site of Testing (Central Laboratories and More), Application (Infectious Diseases and More), End User (Diagnostic Laboratories and More) and Country. The Market Forecasts are Provided in Terms of Value (USD).

In 2021, Germany had the largest in vitro diagnostics (IVD) market size in Europe at over *** billion euros. This was followed by France with a market size of *** billion euros, and Italy at *** billion euros.

In 2023, Germany held the largest share of the in vitro diagnostics market in Europe. This share amounted to approximately **** percent. France and Italy followed at **** and **** percent, respectively.

Snapshot img

In-Vitro Diagnostics (IVD) Market Size 2025-2029

The in-vitro diagnostics market size is valued to increase USD 28.8 billion, at a CAGR of 4.6% from 2024 to 2029. Increasing geriatric population, chronic and infectious diseases will drive the in-vitro diagnostics (ivd) market.

Major Market Trends & Insights

North America dominated the market and accounted for a 44% growth during the forecast period.
By Product Type - Reagents and kits segment was valued at USD 70.30 billion in 2023
By Technology - Immunoassay segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 41.35 billion
Market Future Opportunities: USD 28.80 billion
CAGR : 4.6%
North America: Largest market in 2023

Market Summary

The market represents a significant and continually evolving sector within the healthcare industry. This market encompasses a range of diagnostic tests conducted outside the body, utilizing various core technologies such as immunoassays, molecular diagnostics, and clinical chemistry. The applications of IVDs span from infectious disease testing to genetic screening and drug monitoring. The global adoption of advanced treatment solutions and the increasing geriatric population are major drivers propelling the growth of this market. 
Stringent regulatory bodies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), guide in-vitro diagnostics manufacturers, ensuring the highest standards for accuracy and safety. However, challenges persist, including the high cost of IVDs and the need for continuous innovation to address emerging diseases and diagnostic demands. Despite these hurdles, opportunities abound, particularly in emerging markets and in the development of point-of-care (POC) diagnostics, which offer increased accessibility and convenience. In summary, the In-Vitro Diagnostics Market is a dynamic and essential component of the healthcare industry, driven by technological advancements, demographic shifts, and regulatory requirements.
With a projected growth rate of approximately 5% per year, this market is poised for continued expansion and innovation.

What will be the Size of the In-Vitro Diagnostics (IVD) Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the In-Vitro Diagnostics (IVD) Market Segmented and what are the key trends of market segmentation?

The in-vitro diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product Type

  Reagents and kits
  Instruments
  Others


Technology

  Immunoassay
  Molecular diagnostics
  Clinical chemistry
  Hematology
  Others


Application

  Oncology
  Cardiology
  Autoimmune diseases
  Neurology
  Others


End-user

  Hospitals and clinics
  Research institutes
  Diagnostics laboratories
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By Product Type Insights

The reagents and kits segment is estimated to witness significant growth during the forecast period.

The global IVD market is experiencing significant growth, with reagents and diagnostic kits being key components driving this expansion. Reagents, as chemical substances, play a crucial role in the detection and measurement of target analytes in patient samples. They facilitate various diagnostic tests, ranging from clinical chemistry to molecular diagnostics. Clinical chemistry applications account for a substantial portion of the market, with reagents used to measure substances like glucose, cholesterol, and enzymes in blood samples. These measurements contribute to the assessment of medical conditions such as diabetes and cardiovascular diseases.

Molecular diagnostics, another burgeoning segment, utilizes reagents for techniques like polymerase chain reaction (PCR) and next-generation sequencing. These advanced methods enable the identification of genetic mutations and infectious agents, offering valuable insights for personalized medicine and disease management. Diagnostic kits, which include reagents along with calibrators, controls, and sometimes instruments, provide a complete solution for specific diagnostic tests. They cater to diverse applications, such as urinalysis systems, immunofluorescence assays, microbiology systems, and hematology analyzers. Test performance metrics, such as sensitivity and specificity, are critical in ensuring diagnostic accuracy. Technological advancements, like real-time PCR, digita

The in Vitro Diagnostics Market Report is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, and More), Product (Instruments, Reagents and More), Usability (Disposable IVD Devices, Reusable Equipment), Application (Infectious Diseases, Oncology, Cardiology, and More), End User (Stand-Alone Laboratories, and More), Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

The European In Vitro Diagnostics (IVD) market, valued at approximately €25 billion in 2025, is poised for robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5.5% from 2025 to 2033. This expansion is driven by several key factors. Firstly, the increasing prevalence of chronic diseases like diabetes, cancer, and cardiovascular ailments fuels demand for diagnostic testing. Secondly, advancements in molecular diagnostics and the development of more sophisticated, automated IVD instruments contribute significantly to market growth. Technological innovations such as point-of-care testing and rapid diagnostic tests are also streamlining workflows and enhancing diagnostic accuracy, further stimulating demand. Government initiatives promoting preventative healthcare and early disease detection in European nations bolster the market, as does the rise in personalized medicine, demanding highly specific and targeted diagnostic solutions. Finally, the ongoing integration of IVD with healthcare information systems improves data management and facilitates better patient care, adding another layer to market expansion. However, market growth is not without challenges. Regulatory hurdles and reimbursement complexities in different European countries can slow down market penetration for new technologies. Furthermore, the high cost associated with advanced IVD technologies, especially molecular diagnostics, can create access barriers, especially in resource-constrained healthcare settings. Competition amongst established industry giants like Abbott, Roche, and Siemens, alongside the emergence of innovative smaller players, also shapes market dynamics. Despite these restraints, the market's overall growth trajectory remains positive, propelled by demographic changes, increasing healthcare expenditure, and technological advancements making IVD testing more accessible and effective. The segment of molecular diagnostics is anticipated to experience the most rapid growth, driven by increasing demand for faster and more accurate tests for infectious diseases and genetic disorders. Recent developments include: In March 2023, MGI Tech Co., Ltd. received the CE mark for the DNBSeq-G99 sequencer with an aim to precise sequencing of genetic substances., In December 2022, BioMérieux SA received the CE mark for Vidas Kube automated immunoassay system to diagnose immunochemistry, infectious diseases, and food industry pathogens., In September 2022, Noul Co., Ltd. received the CE-IVD mark for two next-generation diagnostic testing products, miLab Cartridge CER and miLab Cartridge BCM to expand its product line in in-vitro diagnostics systems.. Key drivers for this market are: High Prevalence of Chronic Diseases, Increasing Demand for Point-of-care Diagnostics; Technological Advancements in In-Vitro Diagnostics Devices. Potential restraints include: High Prevalence of Chronic Diseases, Increasing Demand for Point-of-care Diagnostics; Technological Advancements in In-Vitro Diagnostics Devices. Notable trends are: The Instrument Segment is Expected to Hold a Major Share in the Market.

In 2021, Switzerland had the largest in vitro diagnostics (IVD) market size per capita in Europe with almost ** euros spent per person in the IVD industry. This was followed by Germany who had an expenditure of **** euros per person.

Europe In Vitro Diagnostics (IVD) Market size was valued at USD 16.45 Billion in 2024 and is projected to reach USD 24.72 Billion by 2032, growing at a CAGR of 5.3% from 2026 to 2032.

Key Market Drivers:

Increasing Incidence of Chronic Diseases: The increased prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disease is a significant driver of the IVD industry. According to the European Commission's 2020 report, around 60% of adults in the EU have at least one chronic condition. As these diseases require continuous monitoring and management, the demand for in vitro diagnostic testing continues to grow, driving market expansion.

Technological Advancements in IVD Devices: The increased use of advanced technologies, such as molecular diagnostics and point-of-care testing (POCT), is driving the IVD market in Europe.

The global In Vitro Diagnostic (IVD) Products market, valued at $86.86 billion in 2025, is projected to experience robust growth, driven by a Compound Annual Growth Rate (CAGR) of 6.6% from 2025 to 2033. This expansion is fueled by several key factors. The increasing prevalence of chronic diseases like diabetes, cardiovascular conditions, and cancer necessitates frequent diagnostic testing, bolstering market demand. Technological advancements, particularly in molecular diagnostics and point-of-care testing (POCT), are enabling faster, more accurate, and efficient diagnostics, further driving market growth. The rising geriatric population, which is more susceptible to various health issues, also contributes significantly to the market's expansion. Furthermore, government initiatives promoting preventive healthcare and early disease detection are creating favorable market conditions. Hospitals and laboratories remain the largest application segments, but the growth of POCT is expanding access to diagnostics in various settings, including clinics and home healthcare. The market's growth is not without challenges. Regulatory hurdles and stringent approval processes for new IVD products can impede market entry and expansion. High costs associated with advanced diagnostic technologies, particularly molecular diagnostics, can limit accessibility in certain regions. However, the ongoing development of cost-effective diagnostic solutions and the increasing adoption of telemedicine and remote patient monitoring are mitigating these restraints. Major players like Roche, Abbott, Danaher, and Siemens Healthineers dominate the market, leveraging their strong R&D capabilities and extensive distribution networks. The competitive landscape is dynamic, with ongoing innovation and strategic partnerships shaping the market's evolution. Emerging markets in Asia-Pacific and the Middle East & Africa present significant growth opportunities, driven by increasing healthcare spending and improving healthcare infrastructure. The market is segmented by application (hospitals, laboratories, others) and type (immuno diagnostics, chemistry diagnostics, molecular diagnostics, POCT, others), providing a detailed understanding of the various market segments and their growth trajectories. The forecast period of 2025-2033 offers ample opportunity for continued market expansion.

Discover the booming UK In-Vitro Diagnostics (IVD) market! This analysis reveals key trends, drivers, and market size projections for 2025-2033, highlighting opportunities in clinical chemistry, molecular diagnostics, and point-of-care testing. Learn about leading companies and regional market share. Recent developments include: In November 2022, Cepheid reported that it has received the CE mark for Xpert Xpress GBS, a molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS). This molecular test is available in the entire of Europe including the United Kingdom., In October 2022, Avacta, a UK-based developer of cancer immunotherapies and diagnostics, acquired Launch Diagnostics. Launch is an independent in vitro diagnostics distributor in the UK. This acquisition will provide it with established in vitro diagnostic distribution channels in the UK and several other European nations.. Key drivers for this market are: Rising Prevalence of Chronic Diseases, Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics; Increasing Use of Point-of-care (POC) Diagnostics. Potential restraints include: Rising Prevalence of Chronic Diseases, Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics; Increasing Use of Point-of-care (POC) Diagnostics. Notable trends are: Infectious Diseases Segment is Expected to Witness Significant Growth Over the Forecast Period..

The global in vitro diagnostics (IVD) market is experiencing robust expansion, projected to reach a substantial market size by 2033, driven by an estimated Compound Annual Growth Rate (CAGR) of approximately 7.5%. This growth is fueled by a confluence of factors including the increasing prevalence of chronic and infectious diseases, a rising demand for early disease detection and personalized medicine, and significant advancements in diagnostic technologies. The aging global population is a critical demographic driver, as older individuals are more susceptible to various health conditions requiring regular diagnostic testing. Furthermore, growing healthcare expenditure, particularly in emerging economies, coupled with enhanced accessibility to diagnostic services, is contributing to market penetration. The COVID-19 pandemic also served as a significant catalyst, highlighting the critical importance of rapid and accurate IVD testing and accelerating investment in this sector. Innovations in areas like molecular diagnostics, immunoassay, and point-of-care (POC) testing are expanding the scope and efficiency of IVD applications, enabling faster and more accurate diagnoses across a wide spectrum of medical conditions, from cancer and cardiovascular diseases to infectious outbreaks. Despite the promising growth trajectory, the IVD market faces certain restraints. These include the high cost associated with advanced diagnostic equipment and reagents, stringent regulatory hurdles for product approval, and concerns regarding reimbursement policies in various healthcare systems. However, the persistent demand for improved healthcare outcomes and the continuous pursuit of technological innovations are expected to overcome these challenges. The market is segmented across diverse applications, including infectious disease diagnostics, oncology, cardiology, nephrology, and critical care, with infectious diseases consistently representing a dominant segment due to the ongoing threat of global pandemics and endemic infections. The types of IVD products are equally varied, encompassing clinical chemistry, immunoassays, molecular diagnostics, hematology, and microbiology, each catering to specific diagnostic needs and technological advancements. Key players like Abbott Laboratories, Roche Diagnostics, and Siemens Healthcare are at the forefront, investing heavily in research and development to introduce next-generation IVD solutions and expand their global footprint. This in-depth market research report provides a comprehensive analysis of the global In Vitro Diagnostics (IVD) Products and Tests market, encompassing a study period from 2019 to 2033, with a base year of 2025. The report delves into historical trends (2019-2024) and offers detailed forecasts for the period 2025-2033. It aims to equip stakeholders with critical insights to navigate this dynamic and rapidly evolving sector.

The In-Vitro Diagnostic (IVD) market is experiencing robust growth, driven by several key factors. Technological advancements, particularly in molecular diagnostics and point-of-care testing, are enabling faster, more accurate, and more accessible diagnoses. The increasing prevalence of chronic diseases like diabetes and cardiovascular conditions, coupled with a rising geriatric population globally, fuels demand for efficient diagnostic tools. Furthermore, the expanding healthcare infrastructure in emerging economies and the increasing focus on preventive healthcare are contributing significantly to market expansion. Government initiatives promoting early disease detection and improved healthcare access further bolster market growth. While the market is fragmented, with numerous players competing across different segments, leading companies like Abbott, Johnson & Johnson, and Roche maintain a significant market share due to their extensive product portfolios and robust distribution networks. The market is witnessing strong competition, particularly in the development of advanced diagnostic technologies like next-generation sequencing and advanced imaging techniques. The IVD market is segmented by application (hospitals and clinics, diagnostic centers) and type (test equipment, test reagents). Hospitals and clinics currently hold the largest share, driven by the increasing number of patients requiring diagnostic tests. However, the diagnostic center segment is expected to witness faster growth due to the increasing adoption of advanced diagnostic techniques and the convenience offered to patients. Similarly, test equipment is a larger market segment compared to test reagents; however, reagents are experiencing strong growth owing to the rising demand for diagnostic tests and their consumable nature. Regional growth is uneven, with North America and Europe currently dominating the market due to higher healthcare expenditure and technological advancements. However, Asia-Pacific, particularly India and China, are exhibiting significant growth potential due to the rapid expansion of healthcare infrastructure and rising disposable incomes. The overall market trajectory indicates consistent growth throughout the forecast period (2025-2033), though regional variations and technological shifts may influence the specific growth rates in various segments.

In 2022, the in vitro diagnostics market in Europe shrank by around ** percent, by far the biggest drop since 2009. There was a drop of a further **** percent in the market in 2023. These two years of declining growth followed 2021 in which unprecedented growth of almost ** percent was recorded.

The In Vitro Diagnostics (IVD) products market is experiencing robust growth, projected to reach a market size of $83.41 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 3.4% from 2019 to 2033. This growth is fueled by several key factors. The increasing prevalence of chronic diseases globally necessitates more frequent diagnostic testing, driving demand for IVD products. Technological advancements, particularly in molecular diagnostics and immunoassays, are leading to more accurate, rapid, and cost-effective diagnostic solutions. Furthermore, the rising adoption of point-of-care diagnostics, enabling faster diagnosis and treatment initiation, is contributing significantly to market expansion. Government initiatives aimed at improving healthcare infrastructure and strengthening disease surveillance programs in both developed and developing economies also play a substantial role. The market segmentation reveals strong demand across various applications, with hospitals and laboratories remaining major consumers. However, the increasing adoption of home-based testing and the growing prominence of research and academic institutions as users also contribute to the market's dynamism. Key players like Thermo Fisher Scientific, Roche Diagnostics, and Abbott Laboratories dominate the market, leveraging their extensive product portfolios and global reach. The market's regional landscape reflects a significant share held by North America, driven by advanced healthcare infrastructure and higher per capita healthcare spending. Europe follows as a substantial market, showcasing robust growth driven by increasing healthcare expenditure and technological advancements within the region. Asia-Pacific is anticipated to exhibit substantial growth potential, fueled by rapid economic development, rising healthcare awareness, and expanding diagnostic infrastructure. While the market faces challenges such as regulatory hurdles and price pressures, the overall trajectory indicates sustained expansion propelled by the aforementioned drivers. The continued investment in research and development to enhance diagnostic capabilities, alongside the focus on improving healthcare accessibility, will contribute to a consistently growing IVD products market in the coming years.

The global In-Vitro Diagnostics (IVD) market is poised for significant expansion, currently valued at an estimated $150,050 million. This robust growth is driven by a confluence of factors, including the escalating prevalence of chronic diseases such as diabetes and cardiovascular conditions, a growing awareness of early disease detection, and advancements in diagnostic technologies. The market is projected to witness a Compound Annual Growth Rate (CAGR) of approximately 6.5% over the forecast period of 2025-2033, indicating a dynamic and thriving sector. Key segments contributing to this growth include molecular diagnostics, which are instrumental in identifying infectious diseases and genetic disorders, and tissue diagnostics, vital for accurate cancer staging and treatment planning. The increasing demand for personalized medicine and point-of-care testing further fuels innovation and market penetration. Leading companies such as Roche, Abbott, Danaher, and Siemens Healthineers are at the forefront, investing heavily in research and development to introduce novel diagnostic solutions and expand their product portfolios. North America and Europe currently dominate the market, owing to well-established healthcare infrastructures and high adoption rates of advanced diagnostic technologies. However, the Asia Pacific region, particularly China and India, is emerging as a high-growth market due to rising healthcare expenditures, increasing patient populations, and a growing emphasis on preventative healthcare measures. The IVD market's trajectory is further shaped by evolving trends such as the integration of artificial intelligence (AI) and machine learning (ML) for enhanced data analysis and diagnostic accuracy, and the shift towards multiplex assays capable of detecting multiple analytes simultaneously. The miniaturization of diagnostic devices and the proliferation of connected health platforms are also contributing to greater accessibility and efficiency in diagnostic testing. While the market presents immense opportunities, certain restraints, such as stringent regulatory approvals for new diagnostic devices and the high cost of advanced IVD technologies, need to be addressed. Nevertheless, the sustained demand for accurate and timely diagnostic information to guide treatment decisions, coupled with ongoing technological innovations and supportive government initiatives aimed at improving healthcare access, strongly suggests a positive outlook for the global In-Vitro Diagnostics market in the coming years. The market's ability to adapt to evolving healthcare needs and leverage technological advancements will be crucial for sustained growth and its pivotal role in global public health.

The Italian In Vitro Diagnostics (IVD) market, valued at approximately €X million in 2025 (estimated based on provided CAGR and market size), is projected to experience robust growth, driven by factors such as an aging population, rising prevalence of chronic diseases (diabetes, cancer, cardiovascular diseases), and increasing government initiatives to improve healthcare infrastructure. The market's 7.50% CAGR from 2019 to 2033 indicates a consistent upward trajectory. Key segments contributing to this growth include clinical chemistry, molecular diagnostics, and immunoassays, fueled by technological advancements leading to faster, more accurate, and higher-throughput diagnostic testing. The demand for both disposable and reusable IVD devices is expected to remain strong, with hospitals and diagnostic laboratories representing the largest end-user segments. However, challenges such as stringent regulatory approvals, high costs associated with advanced technologies, and potential reimbursement issues could moderate market growth to some extent. The competitive landscape in the Italian IVD market is characterized by the presence of both global giants like Abbott Laboratories, Roche, and Siemens Healthineers, as well as smaller, specialized players. These companies are engaged in strategic initiatives, including product innovation, mergers and acquisitions, and collaborations to strengthen their market position and expand their product portfolio. The focus is shifting towards personalized medicine and point-of-care diagnostics, further boosting market expansion. This trend is particularly relevant in light of Italy's focus on improving healthcare accessibility and efficiency, creating opportunities for innovative IVD solutions. Future growth will likely depend on adapting to evolving healthcare policies, continuous technological advancements, and effective strategies to address the challenges mentioned earlier. The market's expansion will continue to be shaped by the increasing demand for early and accurate disease detection and management. Recent developments include: In April 2023, Biovica International signed a commercial partnership with IT Health Fusion with an aim to commercialize the DiviTum TKa assay in Italy. This is an in-vitro-diagnostic device that is used for semi-quantitative measurement of thymidine kinase activity (TKa) in human serum., In May 2022, the new EU In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) became effective in Italy with effect from May 26, 2022. Whereas certain legacy devices will benefit from transition periods, all new IVDs and certain low-risk IVDs already on the market are now subject to the IVDR requirements.. Key drivers for this market are: Rising Prevalence of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics. Potential restraints include: Rising Prevalence of Chronic Diseases, Increasing Use of Point-of-care (POC) Diagnostics. Notable trends are: Molecular Diagnostics Segment is Expected to Hold a Major Share in the Market Over the Forecast Period.

Europe In Vitro Diagnostics Market Outlook 2031

The Europe in vitro diagnostics market size was USD 15.91 Billion in 2022 and is projected to reach USD 24.26 Billion by 2031 expand at a substantial CAGR 4.8% during the forecast period, 2023–2031. The growth of the market is attributed to the wide prevalence of chronic diseases as well as growing public awareness regarding early detection of life-threatening diseases.



Medical devices, assays, and reagents are key components for in vitro diagnostics (IVD) process, which are used to diagnose a medical condition. Various instruments are also used to analyze tissue samples and bodily fluids obtained from patients and some of the key diagnostic instruments are immunodiagnostics, tissue diagnostics, and molecular diagnostics.

The diagnostics devices are also widely adopted for detecting various infectious diseases and chronic illness such as cardiac disorders, cancer, and diabetes. Furthermore, since the use and handling of in vitro diagnostics necessitates professional experience, diagnosis is carried out in specialist medical facilities using instruments. IVD materials, for example, are used in standalone labs, clinics, and point-of-care settings.



The elderly population is vulnerable to a variety of degenerative and infectious diseases, which is resulting in a wide occurrence of targeted diseases of this group of population. According to a report, the number of people aged 65 and above who are suffering from such diseases in Europe is projected to increase from 18.5 percent in 2014 to 28.7 percent in 2080. Since diagnostic interpretation is required for effective disease treatment, IVDs are important parts of the healthcare industry, especially in the diseases diagnosis.

Europe In Vitro Diagnostics Market Trends, Drivers, Restraints, and Opportunities

• <span style="font-size:12

The In Vitro Diagnostics (IVD) Quality Control Product market is projected to reach $798.5 million in 2025, growing at a CAGR of 1.9% through 2033. Discover key market trends, leading companies, and regional insights in this comprehensive analysis of IVD quality control.

Europe In-Vitro Diagnostics Market valued USD 14.89 Bn in 2023, and is projected to hit USD 18.67 Bn by 2030, driven by growing aging population

The In Vitro Diagnostic (IVD) solutions market is booming, projected to reach $80B in 2025 and grow at a 5% CAGR through 2033. This comprehensive analysis explores market size, key players (Roche, Abbott, Siemens), regional trends, and driving forces behind this rapid expansion in immuno, chemistry, and molecular diagnostics.